5.19
0.02 (0.39%)
前收盘价格 | 5.17 |
收盘价格 | 5.13 |
成交量 | 1,578,581 |
平均成交量 (3个月) | 1,933,471 |
市值 | 894,815,232 |
价格/销量 (P/S) | 101.26 |
股市价格/股市净资产 (P/B) | 1.35 |
52周波幅 | |
利润日期 | 6 Nov 2025 |
营业利益率 (TTM) | -1,105.21% |
稀释每股收益 (EPS TTM) | -2.20 |
季度收入增长率 (YOY) | -23.30% |
总债务/股东权益 (D/E MRQ) | 6.54% |
流动比率 (MRQ) | 19.96 |
营业现金流 (OCF TTM) | -271.99 M |
杠杆自由现金流 (LFCF TTM) | -155.22 M |
资产报酬率 (ROA TTM) | -28.82% |
股东权益报酬率 (ROE TTM) | -45.46% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 混合的 | 混合的 |
Biotechnology (全球的) | 混合的 | 混合的 | |
股票 | Relay Therapeutics, Inc. | 看涨 | 看跌 |
AIStockmoo 评分
分析师共识 | 5.0 |
内部交易活动 | NA |
价格波动 | -4.5 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 4.0 |
平均 | 1.75 |
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971). |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Value |
内部持股比例 | 1.48% |
机构持股比例 | 105.68% |
所有权
姓名 | 日期 | 持有股份 |
---|---|---|
Casdin Capital, Llc | 30 Jun 2025 | 11,398,574 |
52周波幅 | ||
目标价格波幅 | ||
高 | 19.00 (Raymond James, 266.09%) | 购买 |
中 | 15.00 (189.02%) | |
低 | 14.00 (HC Wainwright & Co., 169.75%) | 购买 |
平均值 | 16.00 (208.29%) | |
总计 | 3 购买 | |
平均价格@调整类型 | 3.59 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Guggenheim | 04 Sep 2025 | 15.00 (189.02%) | 购买 | 4.00 |
HC Wainwright & Co. | 26 Aug 2025 | 14.00 (169.75%) | 购买 | 3.54 |
Raymond James | 08 Aug 2025 | 19.00 (266.09%) | 购买 | 3.22 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合